603127 昭衍新藥
按盤價 
17.680 -1.160 (-6.157%) | 2024/09 - 九個月 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -0.864 | 4.823 | 14.024 | 13.335 | 30.369 |
| 總資產報酬率 ROA (%) | -0.719 | 3.894 | 11.367 | 10.474 | 17.738 |
| 投入資產回報率 ROIC (%) | -0.743 | 4.089 | 11.932 | 11.017 | 22.796 | 邊際利潤分析 |
| 銷售毛利率 (%) | 27.480 | 42.617 | 47.898 | 48.733 | 51.381 |
| 營業利潤率 (%) | -5.217 | 21.338 | 54.041 | 42.388 | 33.564 |
| 息稅前利潤/營業總收入 (%) | -10.825 | 14.974 | 47.854 | 41.067 | 33.744 |
| 淨利潤/營業總收入 (%) | -5.561 | 16.476 | 47.320 | 36.686 | 29.150 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | -153.696 | 148.826 | 68.484 | 66.931 | 75.325 |
| 價值變動淨收益/利潤總額(%) | 227.180 | -46.556 | 29.241 | 27.224 | 16.770 |
| 營業外收支淨額/利潤總額(%) | 0.331 | -0.029 | 1.158 | -0.138 | -0.151 | 償債能力分析 |
| 流動比率 (X) | 4.107 | 4.854 | 3.215 | 4.789 | 1.556 |
| 速動比率 (X) | 2.851 | 3.584 | 2.025 | 4.212 | 1.022 |
| 資產負債率 (%) | 16.108 | 17.414 | 20.970 | 16.313 | 41.923 |
| 帶息債務/全部投入資本 (%) | 11.143 | 11.435 | 12.762 | 11.421 | 28.958 |
| 股東權益/帶息債務 (%) | 774.583 | 749.269 | 657.404 | 757.156 | 226.434 |
| 股東權益/負債合計 (%) | 521.552 | 474.155 | 376.548 | 512.423 | 138.617 |
| 利息保障倍數 (X) | 1.936 | -2.355 | -7.016 | -32.515 | 146.543 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 42.372 | 30.710 | 24.369 | 23.317 | 32.663 |
| 存貨周轉天數 (天) | 487.278 | 535.589 | 441.019 | 256.218 | 214.447 |
| 備註： | 即時報價更新時間為 22/11/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
